Pharmacologic agents for weight reduction

Journal of Gender-Specific Medicine

Volumn 5, Issue 5, 2002, Pages 16-21

  Haller, Christine ^a   Schwartz, Janice B ^b  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 1 ADRENERGIC RECEPTOR; AMFEPRAMONE; AMPHETAMINE DERIVATIVE; ANOREXIGENIC AGENT; ANTIMETABOLITE; BENZPHETAMINE; BETA 2 ADRENERGIC RECEPTOR; CAFFEINE; CYTOCHROME P450; DEXFENFLURAMINE; DOPAMINE; EPHEDRINE; FENFLURAMINE; HYDROXYCITRIC ACID; MAZINDOL; METHAMPHETAMINE; MONOAMINE OXIDASE INHIBITOR; NON PRESCRIPTION DRUG; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; OBENIX; OXEDRINE; PHENDIMETRAZINE; PHENMETRAZINE; PHENTERCOT; PHENTERMINE; PHENTERMINE RESIN; PHENTRIDE; PHENYLPROPANOLAMINE; PRO FAST; SENNOSIDE; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE; TETRAHYDROLIPSTATIN; UNINDEXED DRUG; ZANTRYL;

CALORIC INTAKE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; DIET THERAPY; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DYSMENORRHEA; FLATULENCE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; INSOMNIA; KINESIOTHERAPY; LIFESTYLE; OBESITY; PRESCRIPTION; REVIEW; TREMOR; UNITED STATES; WEIGHT REDUCTION; XEROSTOMIA;

ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; CYCLOBUTANES; EPHEDRA; HUMANS; LACTONES; OBESITY; PHYTOTHERAPY; SYMPATHOMIMETICS; WEIGHT LOSS;

EID: 0036767836     PISSN: 15237036     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Prevalence of overweight and obesity among adults: United States, 1999. Hyattsville, MD: National Center for Health Statistics, Health E-Stats, 2000. Available at: http://www.cdc.gov/nchs/products/pubs/pubd/hestats/obese/obse99tab2.htm. Accessed August 16, 2002.
2. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: The evidence report. Obes Res 1998;6(suppl 2):51S-209S.
3. Andersen AE, Holman JE. Males with eating disorders: Challenges for treatment and research. Psychopharmacol Bull 1997;33(3):391-397.
4. Blanck HM, Khan LK, Serdula MK. Use of non-prescription weight loss products: Results from a multistate survey. JAMA 2001;286:930-935.
5. Phelan S, Wadden TA. Combining behavioral and pharmacological treatments for obesity. Obes Res 2002; 10(6):560-574.
6. Craighead LW, Stunkard AJ, O'Brien RM. Behavior therapy and pharmacotherapy for obesity. Arch Gen Psychiatry 1981;38(7):763-768.
7. Lean ME. Obesity: What are the current treatment options? Exp Clin Endocrinol Diabetes 1998;106(suppl 2):22-26.
8. Astrup A, Rossner S. Lessons from obesity management programmes: Greater initial weight loss improves long-term maintenance. Obes Rev 2000;1(1):17-19.
9. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000;343:1833-1838.
10. Lake CR, Gallant S, Masson E, Miller P. Adverse drug effects attributed to phenylpropanolamine: A review of 142 case reports. Am J Med 1990;89:195-208.
11. From the Centers for Disease Control and Prevention. Adverse events associated with ephedrine-containing products: Texas, December 1993-September 1995. JAMA 1996;276(21):1711-1712.
12. Bruno A, Nolte KB, Chapin J. Stroke associated with ephedrine use. Neurology 1993;43:1313-1316.
13. Zaacks SM, Klein L, Tan CD, et al. Hypersensitivity myocarditis associated with ephedra use. J Toxicol Clin Toxicol 1999;37(4):485-489.
14. Doyle H, Kargin M. Herbal stimulant containing ephedrine has also caused psychosis. BMJ 1996;313:756.
15. Theoharides TC. Sudden death of a healthy college student related to ephedrine toxicity from a ma huang-containing drink. J Clin Psychopharmacol 1997;17(5):437-439.
16. Samenuk D, Link MS, Homoud MK, et al. Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine. Mayo Clin Proc 2002;77:12-16.
17. Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000;343:1826-1832.
18. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-588.
19. Department of Health and Human Services. Food and Drug Administration. FDA announces withdrawal of fenfluramine and dexfenfluramine. September 15, 1997. Available at: http://www.fda.gov/cder/news/phen/fenphenpr81597.htm. Accessed August 16, 2002.
20. Silverstone T. Clinical use of appetite suppressants. Drug Alcohol Depend 1986;17:151-167.
21. Wirth A, Krause J. Long-term weight loss with sibutramine: A randomized controlled trial. JAMA 2001;286:1331-1339.
22. Drug interactions. Available at: http://www.fda.gov/cder/drug/drugReactions/default.htm#Drug Metabolism. Accessed August 7, 2002.
23. The Health Research Group. Petition to FDA to ban the diet drug sibutramine (Meridia). HRG Publication #1613. Available at: http://www.citzen.org/publications/release. cfm?ID=7160. Accessed August 7, 2002.
24. Abbott's Reductil [UK name for sibutramine] linked to two deaths in Britain. Reuters Health; March 15, 2002.
25. Carriere F, Renou C, Ransac S, et al. Inhibition of gastrointestinal lipolysis by orlistat during digestion of test meals in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2001;281:G16-G28.
26. Zhi J, Melia AT, Eggers H, et al. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol 1995;35:1103-1108.
27. Sjostrom L, Rissanen A, Andersen T, et al. Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998;352:167-172.
28. Cavaliere H, Floriano I, Medeiros-Neto G. Gastrointestinal side effects of orlistat may be prevented by concomitant prescription of natural fibers (psyllium mucilloid). Int J Obes Relat Metab Disord 2001;25(7):1095-1099.
29. Daly PA, Krieger DR, Dulloo AG, et al. Ephedrine, caffeine, and aspirin: Safety and efficacy for treatment of human obesity. Int J Obes Relat Metab Disord 1993;17(suppl 1):S73-S78.
30. Horton TJ, Geissler CA. Post-prandial thermogenesis with ephedrine, caffeine and aspirin in lean, pre-disposed obese and obese women. Int J Obes Relat Metab Disord 1996;20:91-97.
31. Astrup A, Toubro S, Cannon S, et al. Thermogenic synergism between ephedrine and caffeine in healthy volunteers: A double-blind, placebo-controlled study. Metabolism 1991;40:323-329.
32. Code of Federal Regulations, Title 21-Food and Drugs. Revised as of April 1, 2002. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/ showCFR.cfm?FR=310.545. Accessed August 7, 2002.
33. Boozer CN, Nasser JA, Heymsfield SB, et al. An herbal supplement containing Ma Huang-Guarana for weight loss: A randomized, double-blind trial. Int J Obes Relat Metab Disord 2001;25:316-324.
34. http://www.cdc.gov/mmwr/preview/mmwrhtml/00043335.htm. Accessed August 16, 2002.
35. Tormey WP, Bruzzi A. Acute psychosis due to the interaction of legal compounds: Ephedra alkaloids in 'vigueur fit' tablets, caffeine in 'red bull' and alcohol. Med Sci Law 2001;41(4):331-336.
36. Heymsfield SB, Allison DB, Vasselli JR, et al. Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent. A randomized controlled trial. JAMA 1998;280:1596-1600.